Goldman Sachs’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-159,500
Closed -$15.2M 6513
2025
Q4
$15.2M Hold
159,500
﹤0.01% 2648
2025
Q3
$15.6M Sell
159,500
-5,000
-3% -$518K ﹤0.01% 2508
2025
Q2
$17.7M Buy
164,500
+5,000
+3% +$506K ﹤0.01% 2232
2025
Q1
$16.1M Sell
159,500
-20,000
-11% -$2.01M ﹤0.01% 2236
2024
Q4
$16M Buy
179,500
+20,000
+13% +$1.76M ﹤0.01% 2346
2024
Q3
$13.4M Buy
159,500
+34,000
+27% +$2.68M ﹤0.01% 2437
2024
Q2
$9.66M Sell
125,500
-138,800
-53% -$10.2M ﹤0.01% 2540
2024
Q1
$18.1M Sell
264,300
-41,000
-13% -$2.64M ﹤0.01% 1936
2023
Q4
$17.6M Buy
305,300
+55,300
+22% +$2.95M ﹤0.01% 2016
2023
Q3
$13.2M Hold
250,000
﹤0.01% 2159
2023
Q2
$13.5M Buy
+250,000
New +$13.1M ﹤0.01% 2178
2023
Q1
Sell
-67,300
Closed -$3.11M 5932
2022
Q4
$3.11M Buy
67,300
+52,500
+355% +$2.27M ﹤0.01% 3582
2022
Q3
$573K Sell
14,800
-53,600
-78% -$2.15M ﹤0.01% 4885
2022
Q2
$2.55M Buy
68,400
+14,800
+28% +$602K ﹤0.01% 3835
2022
Q1
$2.37M Buy
53,600
+22,100
+70% +$958K ﹤0.01% 4107
2021
Q4
$1.34M Buy
31,500
+2,600
+9% +$109K ﹤0.01% 4601
2021
Q3
$1.25M Sell
28,900
-63,200
-69% -$2.8M ﹤0.01% 4573
2021
Q2
$3.94M Buy
92,100
+56,300
+157% +$2.37M ﹤0.01% 3564
2021
Q1
$1.38M Buy
35,800
+13,200
+58% +$500K ﹤0.01% 4348
2020
Q4
$812K Buy
+22,600
New +$815K ﹤0.01% 4327
2020
Q3
Sell
-40,000
Closed -$1.4M 5314
2020
Q2
$1.4M Hold
40,000
﹤0.01% 3717
2020
Q1
$1.3M Sell
40,000
-67,400
-63% -$2.63M ﹤0.01% 3572
2019
Q4
$4.86M Buy
107,400
+95,200
+780% +$3.98M ﹤0.01% 2989
2019
Q3
$496K Sell
12,200
-1,300
-10% -$55.1K ﹤0.01% 4456
2019
Q2
$580K Sell
13,500
-14,000
-51% -$538K ﹤0.01% 4316
2019
Q1
$1.05M Buy
+27,500
New +$1.05M ﹤0.01% 4018
2018
Q4
Sell
-300
Closed -$12K 5249
2018
Q3
$12K Hold
300
﹤0.01% 5458
2018
Q2
$10K Sell
300
-258,700
-100% -$7.8M ﹤0.01% 5543
2018
Q1
$7.08M Buy
259,000
+258,700
+86,233% +$7.03M ﹤0.01% 2626
2017
Q4
$7K Sell
300
-2,600
-90% -$71.7K ﹤0.01% 6228
2017
Q3
$85K Sell
2,900
-16,000
-85% -$442K ﹤0.01% 6115
2017
Q2
$524K Sell
18,900
-27,200
-59% -$722K ﹤0.01% 5056
2017
Q1
$1.15M Sell
46,100
-44,100
-49% -$1.07M ﹤0.01% 4250
2016
Q4
$1.95M Sell
90,200
-35,400
-28% -$772K ﹤0.01% 3876
2016
Q3
$2.99M Buy
125,600
+110,900
+754% +$2.65M ﹤0.01% 3484
2016
Q2
$344K Sell
14,700
-2,000
-12% -$43.3K ﹤0.01% 5220
2016
Q1
$314K Sell
16,700
-81,200
-83% -$1.43M ﹤0.01% 5236
2015
Q4
$1.8M Sell
97,900
-113,300
-54% -$2.03M ﹤0.01% 3724
2015
Q3
$3.47M Buy
211,200
+114,200
+118% +$1.95M ﹤0.01% 3224
2015
Q2
$1.72M Sell
97,000
-205,900
-68% -$3.68M ﹤0.01% 3991
2015
Q1
$5.38M Buy
302,900
+111,400
+58% +$1.76M ﹤0.01% 2816
2014
Q4
$2.54M Buy
191,500
+11,400
+6% +$146K ﹤0.01% 3605
2014
Q3
$2.13M Sell
180,100
-100,900
-36% -$1.27M ﹤0.01% 3871
2014
Q2
$3.59M Sell
281,000
-396,500
-59% -$5.16M ﹤0.01% 3389
2014
Q1
$9.16M Sell
677,500
-955,300
-59% -$12.5M ﹤0.01% 2447
2013
Q4
$19.6M Buy
1,632,800
+1,117,800
+217% +$13.2M 0.01% 1756
2013
Q3
$6.05M Sell
515,000
-65,500
-11% -$709K ﹤0.01% 2739
2013
Q2
$5.38M Buy
+580,500
New +$4.92M ﹤0.01% 2662

Other funds holding BSX

Goldman Sachs's BSX Position: Q1 2026 in Review

Goldman Sachs increased its Boston Scientific (BSX) stake by 14% in Q1 2026, buying an estimated $185M and bringing the position to 18,891,624 shares worth $1.19B. The position accounts for 0.14% of the portfolio, ranked #133.

Goldman Sachs first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.58B in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Goldman Sachs held 18,891,624 shares of Boston Scientific worth $1.19B as of Q1 2026.
  • Goldman Sachs bought 2,312,707 Boston Scientific shares in Q1 2026, an estimated $185M.
  • Boston Scientific made up 0.14% of Goldman Sachs's portfolio in Q1 2026, its #133 holding.
  • Goldman Sachs first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Boston Scientific position peaked at $1.58B in Q4 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.